Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Lilly | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Lilly

Revenues up 3% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Lilly
1Q Revenues: $5.1 billion (+3%)
1Q Earnings: $4.2 billion (earnings were $1.2 billion 1Q18)
Comments: Key growth products launched since 2014, including Trulicity, Taltz, Verzenio, Basaglar, Olumiant, Jardiance, Cyramza and Emgality represented approximately 39% of revenue. Trulicity sales were $879.7 million in the quarter, up 30%. Taltz sales were up 72% to $252.5 million. Basaglar sales were $251.4 million, up 51%. Verzenio sales were $109.4 million, up from $29.7 million in 1Q18. Alimta sales were flat at $499.2 million, with U.S. revenue up 15% to $281.8 million, and revenue outside the U.S. down 15% to $217.4 million, driven by entry of generic pemetrexed in Germany. Humalog sales were down 8% to $730.8 million, driven by decreased demand. Cialis sales were down 38% to $308.2 million due to generic competition. Earnings reflect the gain on the divestiture of the Elanco Animal Health business.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters